CoChat
Sign Up
Cited by 174Medical Imaging Techniques and ApplicationsOptical Imaging and Spectroscopy TechniquesPhotoacoustic and Ultrasonic Imaging

Advances in imaging mouse tumour models in vivo

Open access
Lyons, Scott K·2005·The Journal of Pathology
DOI 10.1002/path.1697
Open this paper in CoChat — free accountOpen PDF

Abstract

Significant progress has been made recently in the variety of ways that cancer can be non‐invasively imaged in murine tumour models. The development and continued refinement of specialized hardware for an array of small animal imaging methodologies are only partly responsible. So too has been the development of new imaging techniques and materials that enable specific, highly sensitive and quantitative measurement of a wide range of tumour‐related parameters. Included amongst these new materials are imaging probes that selectively accumulate in tumours, or that become activated by tumour‐specific molecules in vivo. Other tumour imaging strategies have been developed that rely upon the detection of reporter transgene expression in vivo, and these too have made a significant impact on both the versatility and the specificity of tumour imaging in living mice. The biological implications resulting from these latest advances are presented here, with particular emphasis on those associated with MRI, PET, SPECT, BLI, and fluorescence‐based imaging modalities. Taken together, these advances in tumour imaging are set to have a profound impact on our basic understanding of in vivo tumour biology and will radically alter the application of mouse tumour models in the laboratory. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.1697

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MRI has a spatial resolution of 25-50 μm but requires a significant amount of magnetic dye treatment of transplanted cells, has limited sensitivity, and requires considerably complex and expensive equipment.

    “MRI is a useful technique for visualizing transplanted cells in vivo and has a spatial resolution of 25–50 μm but requires a significant amount of magnetic dye treatment of transplanted cells, has limited sensitivity, and requires considerably complex and expensive equipment (Lee et al., 2007; Lyons, 2005”

    From Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis (2008) · cites this paper as Lyons, 2005

    Table 1 (Conclusions; page not provided) supports MRI's high spatial resolution and low sensitivity, but gives a resolution of 25–100 μm, not 25–50 μm. The MRI imaging section describes contrast probes, not a requirement for substantial magnetic-dye treatment of transplanted cells. The paper notes that equipment costs vary between modalities but does not specifically describe MRI equipment as complex and expensive. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 90

  1. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
  2. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645.
  3. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034-1039.
  4. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogen- esis with a conjugate of HPMA copolymer and TNP-470. Nature Med 2004; 10: 255-261.
  5. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
  6. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-) p53(-/-) mice. Cancer Cell 2004; 6: 229-240.
  7. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1: 289-298.
  8. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
  9. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev Cancer 2002; 2: 11-18.
  10. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-580.
  11. Goertzen AL, Meadors AK, Silverman RW, Cherry SR. Simulta- neous molecular and anatomical imaging of the mouse in vivo. Phys Med Biol 2002; 47: 4315-4328.
  12. Rehemtulla A, Hall DE, Stegman LD, et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging 2002; 1: 43-55.
  13. Ray P, De A, Min JJ, Tsien RY, Gambhir SS. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 2004; 64: 1323-1330.
  14. Ponomarev V, Doubrovin M, Serganova I, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004; 31: 740-751.
  15. Ichikawa T, Hogemann D, Saeki Y, et al. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002; 4: 523-530.
  16. Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, Weissle- der R. In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res 2004; 64: 1579-1583.
  17. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnol 2000; 18: 321-325.
  18. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003; 20: 733-744.
  19. Yang M, Li L, Jiang P, Moossa AR, Penman S, Hoffman RM. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc Natl Acad Sci U S A 2003; 100: 14 259-14 262.
  20. Adams JY, Johnson M, Sato M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nature Med 2002; 8: 891-897.
  21. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002; 62: 1862-1867.
  22. Serganova I, Doubrovin M, Vider J, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004; 64: 6101-6108.
  23. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcrip- tional regulation of p53-dependent genes with positron emis- sion tomography in vivo. Proc Natl Acad Sci U S A 2001; 98: 9300-9305.
  24. Sato M, Johnson M, Zhang L, et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003; 8: 726-737.
  25. Iyer M, Salazar FB, Lewis X, et al. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 2004; 10: 545-552.
  26. Ray S, Paulmurugan R, Hildebrandt I, et al. Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther 2004; 15: 681-690.
  27. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003; 63: 7042-7046.
  28. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nature Rev Cancer 2002; 2: 251-265.
  29. Sundaresan G, Paulmurugan R, Berger F, et al. MicroPET imag- ing of Cre-loxP-mediated conditional activation of a herpes sim- plex virus type 1 thymidine kinase reporter gene. Gene Ther 2004; 11: 609-618.
  30. Laxman B, Hall DE, Bhojani MS, et al. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A 2002; 99: 16 551-16 555.
  31. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nature Med 2003; 9: 969-973.
  32. Zhang GJ, Safran M, Wei W, et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nature Med 2004; 10: 643-648.
  33. Luker GD, Sharma V, Pica CM, et al. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 2002; 99: 6961-6966.
  34. Luker GD, Sharma V, Pica CM, Prior JL, Li W, Piwnica- Worms D. Molecular imaging of protein-protein interactions: controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer Res 2003; 63: 1780-1788.
  35. Paulmurugan R, Umezawa Y, Gambhir SS. Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci U S A 2002; 99: 15 608-15 613.
  36. Paulmurugan R, Massoud TF, Huang J, Gambhir SS. Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res 2004; 64: 2113-2119.
  37. Luker KE, Piwnica-Worms D. Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods Enzymol 2004; 385: 349-360.
  38. Moffat BA, Reddy GR, McConville P, et al. A novel polyacry- lamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003; 2: 324-332.
  39. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004; 64: 1821-1827.
  40. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003; 63: 2723-2727.
  41. Weissleder R, Moore A, Mahmood U, et al. In vivo magnetic resonance imaging of transgene expression. Nature Med 2000; 6: 351-355.
  42. Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003; 2: 581-587.
  43. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nature Rev Cancer 2004; 4: 551-561.
  44. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004; 3: 1-8.
  45. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002; 62: 6146-6151.
  46. Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer alpha(v)-integrin expression with (64)Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004; 6: 350-359.
  47. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnol 2004; 22: 701-706.
  48. Visser GW, van der Wilt CL, Wedzinga R, Peters GJ, Her- scheid JD. 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results. Nucl Med Biol 1996; 23: 333-342.
  49. Collingridge DR, Carroll VA, Glaser M, et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002; 62: 5912-5919.
  50. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 2000; 97: 2785-2790.
  51. Gambhir SS, Barrio JR, Phelps ME, et al. Imaging adenoviral- directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A 1999; 96: 2333-2338.
  52. De A, Lewis XZ, Gambhir SS. Noninvasive imaging of lentiviral- mediated reporter gene expression in living mice. Mol Ther 2003; 7: 681-691.
  53. Dubey P, Su H, Adonai N, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A 2003; 100: 1232-1237.
  54. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nature Biotechnol 2003; 21: 405-413.
  55. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002; 16: 336-351.
  56. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004; 64: 4906-4911.
  57. Contag CH, Ross BD. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 2002; 16: 378-387.
  58. Bhaumik S, Walls Z, Puttaraju M, Mitchell LG, Gambhir SS. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing. Proc Natl Acad Sci U S A 2004; 101: 8693-8698.
  59. Massoud TF, Paulmurugan R, Gambhir SS. Molecular imaging of homodimeric protein-protein interactions in living subjects. FASEB J 2004; 18: 1105-1107.
  60. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003; 20: 745-756.
  61. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000; 2: 491-495.
  62. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 2002; 99: 377-382.
  63. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22: 6865-6872.
  64. Pichler A, Prior JL, Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A 2004; 101: 1702-1707.
  65. Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004; 3: 9-23.
  66. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346.
  67. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 443-453.
  68. Yang M, Baranov E, Jiang P, et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 2000; 97: 1206-1211.
  69. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous deliv- ery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-2710.
  70. Yamamoto N, Yang M, Jiang P, et al. Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging. Cancer Res 2003; 63: 7785-7790.
  71. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725.
  72. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003; 63: 7870-7875.
  73. Citrin D, Scott T, Sproull M, Menard C, Tofilon PJ, Cam- phausen K. In vivo tumor imaging using a near-infrared-labeled endostatin molecule. Int J Radiat Oncol Biol Phys 2004; 58: 536-541.
  74. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, library- derived fluorescent peptide. Cancer Res 2004; 64: 6247-6251.
  75. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med 2001; 7: 743-748.
  76. Marten K, Bremer C, Khazaie K, et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 2002; 122: 406-414.
  77. Messerli SM, Prabhakar S, Tang Y, et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004; 6: 95-105.
  78. Shah K, Tung CH, Chang CH, et al. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res 2004; 64: 273-278.
  79. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis, and characterization of urokinase plasminogen-activator- sensitive near-infrared reporter. Chem Biol 2004; 11: 99-106.
  80. Larson DR, Zipfel WR, Williams RM, et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 2003; 300: 1434-1436.
  81. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 2004; 15: 79-86.
  82. Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol 2003; 21: 41-46.
  83. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnol 2004; 22: 969-976.
  84. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002; 99: 12 617-12 621.
  85. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nature Biotechnol 2004; 22: 93-97.
  86. Graves EE, Weissleder R, Ntziachristos V. Fluorescence molecu- lar imaging of small animal tumor models. Curr Mol Med 2004; 4: 419-430.
  87. Ntziachristos V, Schellenberger EA, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A 2004; 101: 12 294-12 299.
  88. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophys- iology using intravital microscopy. Nature Rev Cancer 2002; 2: 266-276.
  89. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nature Rev Cancer 2003; 3: 921-930.
  90. Holland EC. Mouse models of human cancer as tools in drug development. Cancer Cell 2004; 6: 197-198. J Pathol 2005; 205: 194-205

Cited by

Sorted by citations

Authors
Lyons, S. K.
Corresponding author
Lyons, Scott K
ORCID
Lyons, Scott K
Venue
The Journal of Pathology
Publisher
Wiley
Published
2005-01
Volume
205
Issue
2
Pages
194-205
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
DOI
10.1002/path.1697
OpenAlex
W2096031499
Cited by
174
References
4
Citations by year
2025: 2 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 7 · 2013: 18 · 2012: 13
FWCI
2.93
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 9 d)
Locations
  • The Journal of Pathology (publishedVersion)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
  • Physical Sciences › Engineering › Biomedical Engineering › Photoacoustic and Ultrasonic Imaging
Keywords
tumor imaging, mouse tumor model, non-invasive imaging, magnetic resonance imaging, PET, SPECT, bioluminescence imaging, fluorescence imaging, tumor biology
MeSH terms
Animals, Disease Models, Animal, Luminescent Measurements, Magnetic Resonance Imaging, Neoplasms, Experimental, Tomography, Emission-Computed, Gene Expression Regulation, Neoplastic, Transgenes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review